In Black Mirror‘s season 7 premiere, "Common People," creators Charlie Brooker and Bisha K. Ali deliver a harrowing narrative that mirrors our escalating entanglement with subscription-based living.
What To Know: The episode (spoilers ahead) follows Mike (Chris O’Dowd) and Amanda (Rashida Jones), a couple whose modest existence is upended when Amanda is diagnosed with a terminal brain tumor. Enter Rivermind, a tech firm offering a lifeline: replace the tumor with synthetic brain tissue that streams her consciousness back into her body, for a monthly fee.
Initially, the subscription fee seems manageable. But as Rivermind introduces higher-priced tiers, Amanda begins involuntarily spouting advertisements, and the couple’s financial strain intensifies. Mike resorts to degrading acts on a livestreaming platform, DumDummies, to afford temporary “Lux” passes that grant Amanda brief moments of normalcy.
See also: Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path
Ultimately, Amanda, desiring an end to her fragmented existence, asks Mike to euthanize her during one of her ad-induced blackouts. The episode concludes with Mike preparing for a final, desperate act, underlining the devastating toll of commodified survival.
Why It Matters: Brooker describes the ending to Entertainment Weekly as "particularly chilling," highlighting the inescapable grip of profit-driven systems on personal lives.
The episode’s critique extends beyond fictional tech, reflecting real-world trends: Netflix NFLX recently raised its standard ad-free plan to $17.99, and Apple AAPL increased its monthly AppleCare+ fees for iPhones. These incremental hikes exemplify how popular services are increasingly gated behind paywalls, turning basic needs into premium commodities.
"Common People" serves as a reminder of the human cost embedded in our subscription-saturated society, where the line between necessity and luxury blurs, and the price of survival continues to climb.
Read next: Bearish Analyst Regrets Not Upgrading Netflix To Buy In 2023
Photo courtesy: Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.